Michael Alaimo

About Michael Alaimo

Experienced, field-based Senior Medical Science Liaison (MSL) focused on Hematology, Solid Tumor Oncology, and Immunotherapy (I/O).Specialties: Medical Affairs, KOL Engagement Strategy, Scientific & Medical Communications, Superior Presentation Skills, MSL Training and Development, Investigator Initiated Research, Medical Education, Medical Publications, Clinical Research, KOL Segmentation, Field Deployment Strategy, Competitive Insights, Advisory Board Strategy, Sales Training, HEOR.

Experience

1. Senior Medical Science Liaison - Hematology Oncology

   Takeda Oncology

   Aug 2018 — Present · Raleigh-Durham, NC, US

   Field-based Senior Medical Science Liaison (MSL) in immuno-oncology, experienced in establishing collaborative relationships with global, national, and local KOLs, as well as community practice HCPs (MDs, APPs, BCOPs), serving as a bridge between clinical development and the medical community. Responsible for site selection and activation for company-sponsored clinical trials, evaluating investigator-initiated research ideas, working throughout a product’s clinical and commercial lifecycle to identify gaps and potentially inform strategic decision-making through delivery of medical and scientific education. • Supporting the scientific development & commercialization of marketed Multiple Myeloma products Ninlaro (ixazomib) and Velcade (bortezomib); as well as the Leukemia product Iclusig (ponatinib) in CML and Ph+ ALL.• Molecule Lead: TAK-981 (Subasumstat), a novel SUMOylation inhibitor for CD20+ lymphomas, CD38+ myeloma, and solid tumors.• Early clinical development support for TAK-007, a novel, off-the-shelf CAR NK-cell therapy for CD19+ B-cell malignancies.• Committed to the advancement of innovative development pipeline therapies including Pevonedistat in MDS, CMML and AML; Alisertib in AML; and immunocytokine Modakafusp / TAK-573 (CD38-IFNα attenukine) in MM.• Therapeutic areas of interest include: Multiple Myeloma (MM), B-cell Non-Hodgkin Lymphoma (B-NHL), Chronic Lymphocytic Leukemia (CLL), T-cell Lymphoma (PTCL, CTCL), Chronic Myeloid Leukemia (CML), Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia (APL), Amyloidosis, Hodgkin Lymphoma (HL), Myeloproliferative Neoplasms (polycythemia vera, essential thrombocythemia, and myelofibrosis), Hematopoietic Stem Cell Transplantation (HSCT), Graft vs Host Disease (GvHD), Neutropenia; CAR-T, CAR-NK & CAR-γδ (gamma-delta) T cell therapies.

Education

• Lehigh University

  PhD, Analytical Chemistry

  1988 — 1993

• Commonwealth University-Bloomsburg

  B.S., Chemistry, Physics

  1984 — 1988

Skills

• Nmr
• Qbd & Pat
• Cmc
• Structural Spectroscopy
• Cmc Project Management
• University Teaching
• Oncology
• Cgmp Compliance
• Natural Products
• Scientific Writing
• Immunology
• Peptide Structure
• Investigator Initiated Trials
• Mentoring Direct Reports
• Cross-Functional Teams
• Neurology
• Inflammation
• Clincal Supply Chain
• Small Molecules
• Gmp
• Hplc
• Hematology
• Analytical Chemistry
• Spectroscopy
• Quality by Design
• Clinical Trials
• Polymer Characterization
• Regulatory Documentation
• Key Opinion Leaders